血液生物标志物与长期衰弱风险:瑞典AMORIS队列研究
识别出四个类别,除参考类别外,贫血类、糖尿病类和肝脏类均与衰弱和死亡风险升高相关。在患者中监测这些常见生物标志物可能有助于早期发现和预防衰弱。
要点
- 贫血类(低铁标志物、高炎症标志物)与衰弱风险升高相关(HR=1.54)。
- 糖尿病类(高血糖、高果糖胺)与衰弱风险升高相关(HR=1.59)。
- 肝脏类(高肝酶)与衰弱风险升高相关(HR=1.15)。
核心结论
- 不同组合的常见生物标志物与衰弱发生相关,监测这些标志物可能有助于早期发现和预防衰弱。
主要发现
- 识别出四个类别:参考类(81.7%)、贫血类(5.8%)、糖尿病类(6.5%)和肝脏类(6.0%)。
- 与参考类相比,贫血类衰弱HR=1.54(95%CI 1.38, 1.73),死亡HR=1.76(95%CI 1.65, 1.87)。
- 糖尿病类衰弱HR=1.59(95%CI 1.43, 1.77),死亡HR=1.74(95%CI 1.64, 1.85)。
- 肝脏类衰弱HR=1.15(95%CI 1.01, 1.30),死亡HR=1.40(95%CI 1.31, 1.50)。
- 性别分层分析未显示男女间有实质性差异。
临床怎么用
- 在老年患者中监测常见生物标志物组合可能有助于早期识别衰弱高风险个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Frailty is associated with reduced quality of life, poor health outcomes, and death. Past studies have investigated how specific biomarkers are associated with frailty but understanding biomarkers in concert with each other and the associated risk of frailty is critical for clinical application. METHODS: Using a sample aged ≥59 years at baseline from the Swedish AMORIS (Apolipoprotein MOrtality RISk) cohort (n = 19 341), with biomarkers measured at baseline (1985-1996), we conducted latent class analysis with 18 biomarkers and used Cox models to determine the association between class and frailty and all-cause mortality. RESULTS: Four classes were identified. Compared to the largest class, the Reference class (81.7%), all other classes were associated with increased risk of both frailty and mortality. The Anemia class (5.8%), characterized by comparatively lower iron markers and higher inflammatory markers, had hazard ratio (HR) = 1.54, 95% confidence interval (CI) 1.38, 1.73 for frailty and HR = 1.76, 95% CI 1.65, 1.87 for mortality. The Diabetes class (6.5%) was characterized by higher glucose and fructosamine, and had HR = 1.59, 95% CI 1.43, 1.77 for frailty and HR = 1.74, 95% CI 1.64, 1.85 for mortality. Finally, the Liver class (6.0%), characterized by higher liver enzyme levels, had HR = 1.15, 95% CI 1.01, 1.30 for frailty and HR = 1.40, 95% CI 1.31, 1.50 for mortality. Sex-stratified analyses did not show any substantial differences between men and women. CONCLUSIONS: Distinct sets of commonly available biomarkers were associated with development of frailty and monitoring these biomarkers in patients may allow for earlier detection and possible prevention of frailty, with the potential for improved quality of life.
引用
- Wennberg AM, Ding M, Ebeling M, et al. Blood-Based Biomarkers and Long-term Risk of Frailty-Experience From the Swedish AMORIS Cohort. J Gerontol A Biol Sci Med Sci. 2021. PMID: 33979435. doi:10.1093/gerona/glab137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。